ELI LILLY & CO

Discover Eli Lilly’s breakthrough clinical results: EloraTZP’s 9.5 kg weight loss, Foundayo’s cardio‑safety, and EBGLYSS’s rapid atopic dermatitis relief.

Discover Eli Lilly’s new obesity and diabetes drugs: tirzepatide (Zepbound) beats Wegovy for weight loss and oral forglipron rivals semaglutide in blood‑sugar control.

Explore Eli Lilly’s cardiometabolic breakthroughs—Foundayo, Retatrutide, and EloraTZP—showing 12–14% weight loss, HbA1c drop, and safe GI profiles poised for FDA/EMA approval.

Discover how Eli Lilly’s Q2 2024 results and GLP‑1 drugs Mounjaro & Zepbound drive record sales, superior weight loss, and a bullish market outlook.

Explore Eli Lilly’s latest moves—weight‑loss breakthroughs, KRAS‑targeted oncology, and rising institutional bets—ahead of the 5 August earnings.

How Eli Lilly’s cell‑based platform strategy drives rapid, scalable therapies across diabetes, oncology and neuro‑degeneration, blending manufacturing innovation with promising early clinical results.

See why Eli Lilly’s GLP‑1 drugs Mounjaro and Zepbound hit a new all‑time high and how the company’s share‑sale strategy fuels future growth.

Explore how Eli Lilly’s AI‑driven R&D and targeted acquisitions are reshaping its pipeline, cutting costs, and battling patent cliffs in a competitive pharma market.

Explore how Eli Lilly’s Medicare weight‑loss rollout, Centessa acquisition, and breakthrough oncology drug Jaypirca fuel a rally in defensive healthcare stocks.

Explore Eli Lilly’s dual obesity strategy: Retatrutide’s multi‑modal benefits vs. Foundayo’s oral GLP‑1 breakthrough, market‑access, patent, and M&A insights.